Following the reclassification of gliomas according to the 2016 WHO classification, we investigated the role of TERT promoter mutations, EGFR amplification, PTEN deletion and MGMT promoter methylation in molecular glioma subgroups. This evidence concerns the gene MGMT and central nervous system cancer.